We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact us so we can address the problem.
Retraction Note: therapeutic stimulation of GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment
© The Author(s). 2016
- Received: 5 August 2016
- Accepted: 11 August 2016
- Published: 30 August 2016
The original article was published in Journal of Diabetes & Metabolic Disorders 2015 14:15
The Editors are retracting this article  due to overlap with previous publications, most notably [2, 3]. We apologise for any inconvenience caused. We have been unable to contact the authors regarding the retraction of their article.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Sharma A, Paliwal G, Upadhyay N, Tiwari A. Therapeutic stimulation of GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment. J Diab Metabol Disord. 2015;14:15.View ArticleGoogle Scholar
- Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care. 2003;26:2929–40.View ArticlePubMedGoogle Scholar
- Kountz D. The dipeptidyl peptidase (DPP)-4 inhibitors for type 2 diabetes mellitus in challenging patient groups. Adv Ther. 2013;30:1067–85.View ArticlePubMedPubMed CentralGoogle Scholar